Month: September 2024

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR...

SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) — The Awareness Group LLC (TAG), founder of the TAG GRID and an emerging leader in the alternative energy space which recently announced it signed a binding letter of intent to merge with Freedom Holdings, Inc. (OTC PINK: FHLD), is excited to announce its new National Solar Power Purchase Agreement (PPA) program at the RE+ 24 Tradeshow at the Anaheim Convention Center & Campus in Anaheim, California, from September 9 – 12. The TAG GRID, the cornerstone of TAG’s aggressive growth strategy, is set to revolutionize the solar energy landscape with this new PPA program. This groundbreaking initiative is available nationwide in states where PPAs are permitted and offers an exclusive opportunity for sales organizations and contractors within the TAG GRID. The program is designed...

ABSECON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) — Absecon Bancorp (the “Company”) (OTC, trading as ASCN), the bank holding company of First National Bank of Absecon, an Atlantic County New Jersey based community bank, announced today that its Board of Directors declared a regular quarterly cash dividend in the amount of $0.75 per share, payable on September 30, 2024 to shareholders of record as of September 17, 2024. The First National Bank of Absecon, a nationally chartered bank headquartered in Absecon, New Jersey, has a long history of serving the community since its establishment in 1916. The company is a community bank focused on providing deposit and loan products to retail customers and to small and mid-sized businesses from its primary market area in Atlantic County, New Jersey, and secondary markets consisting of portions...

PONTE VEDRA, Fla., Sept. 09, 2024 (GLOBE NEWSWIRE) — North Avenue Capital, a leader in innovative financing solutions for rural America, is making a significant addition to its lending products thereby extending its reach into urban and suburban communities. As of July 1, 2024, North Avenue Capital is now offering SBA 7(a) loans nationwide, doubling down on its government-guaranteed lending expertise while broadening its service to small businesses beyond rural America. For the past decade, North Avenue Capital has partnered with the USDA to support rural communities with strategic financial support in the form of USDA OneRD loans. After closing nearly $1 billion in small business loans for rural communities, NAC is extending its expertise to SBA 7(a) loans in amounts of $500,000 to $5 million. This move reflects North Avenue Capital’s...

Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutidePlacebo-adjusted reductions in body weight of up to a mean of 8.3% with dapiglutide after 13 weekly doses Dapiglutide treatment with doses up to 13 mg was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Higher doses up to 26 mg over a 28-week treatment period are being evaluated in the ongoing Part 2 of the trial with topline results expected in the first half of 2025Copenhagen, Denmark, 9 September 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and...

J.P. Morgan Structured Products B.V. financial statements for the six month period ended 30 June 2024Attachment2024 – JPM SP BV (Interim) Final

BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a multi-year commercial supply contract with a global healthcare company for the supply of DefenCath® (taurolidine and heparin) to its facilities in the US. The company, which provides healthcare services to more than 2,000 clinics in the United States, expects to initially target the utilization of DefenCath in up to 4,000 patients nationally, that would be prioritized based upon medical need. CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in...

Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services veterinarian.Dr. Husby brings to PetVivo more than a decade of experience and accomplishment in animal health. This has involved clinical practice and research experience at leading animal clinics and educational institutions, including Columbia Equine Clinic, Cascade Animal Clinic, Banfield Pet Hospital and Oregon State...

Reference is made to the announcement on 15 May 2024, regarding the letter of intent between SKEL fjárfestingafélag hf. (“SKEL“) and Samkaup hf. (“Samkaup“), reg.no. 571298-3769, concerning the merger of Samkaup and certain companies within the SKEL group, specifically Orkan IS ehf., Löður ehf., Heimkaup ehf., and Lyfjaval ehf. (the “Merging Companies“). Since the signing of the letter of intent, the parties have conducted financial, tax, and legal due diligence on Samkaup and the merging companies. The results of the due diligence have been reviewed, and an addendum to the letter of intent, originally signed on May 15, has been executed. The terms of the letter remain largely unchanged, except for the agreed exchange ratios. Samkaup shareholders will hold 52.5% of the merged company, while Heimkaup...